Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication

Xiao Song Zhong, Maiko Matsushita, Jason Plotkin, Isabelle Riviere, Michel Sadelain

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

To enhance the strength of activation afforded by tumor antigen-specific receptors, we investigated the effect of adding combined CD28 and 4-1BB costimulatory signaling domains to a chimeric antigen receptor (CAR) specific for prostate-specific membrane antigen (PSMA). Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3 cytoplasmic domains in primary human CD8 T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice. Upon in vitro exposure to PSMA, the P28BBZ receptor-induced the strongest PI 3 Kinase/Akt activation and Bcl-X L expression, and the least apoptosis in transduced peripheral blood CD8 T cells. These findings further support the concept of integrating optimized costimulatory properties into recombinant antigen receptors to augment the survival and function of genetically targeted T cells within the tumor microenvironment.

Original languageEnglish
Pages (from-to)413-420
Number of pages8
JournalMolecular Therapy
Volume18
Issue number2
DOIs
Publication statusPublished - 2010 Feb
Externally publishedYes

Fingerprint

Antigen Receptors
Phosphatidylinositol 3-Kinases
T-Lymphocytes
Neoplasms
Tumor Microenvironment
SCID Mice
Neoplasm Antigens
Cell Survival
Apoptosis
Cytokines
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication. / Zhong, Xiao Song; Matsushita, Maiko; Plotkin, Jason; Riviere, Isabelle; Sadelain, Michel.

In: Molecular Therapy, Vol. 18, No. 2, 02.2010, p. 413-420.

Research output: Contribution to journalArticle

@article{e2ebf602487f4de690fdb51792dd1e2e,
title = "Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication",
abstract = "To enhance the strength of activation afforded by tumor antigen-specific receptors, we investigated the effect of adding combined CD28 and 4-1BB costimulatory signaling domains to a chimeric antigen receptor (CAR) specific for prostate-specific membrane antigen (PSMA). Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3 cytoplasmic domains in primary human CD8 T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice. Upon in vitro exposure to PSMA, the P28BBZ receptor-induced the strongest PI 3 Kinase/Akt activation and Bcl-X L expression, and the least apoptosis in transduced peripheral blood CD8 T cells. These findings further support the concept of integrating optimized costimulatory properties into recombinant antigen receptors to augment the survival and function of genetically targeted T cells within the tumor microenvironment.",
author = "Zhong, {Xiao Song} and Maiko Matsushita and Jason Plotkin and Isabelle Riviere and Michel Sadelain",
year = "2010",
month = "2",
doi = "10.1038/mt.2009.210",
language = "English",
volume = "18",
pages = "413--420",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication

AU - Zhong, Xiao Song

AU - Matsushita, Maiko

AU - Plotkin, Jason

AU - Riviere, Isabelle

AU - Sadelain, Michel

PY - 2010/2

Y1 - 2010/2

N2 - To enhance the strength of activation afforded by tumor antigen-specific receptors, we investigated the effect of adding combined CD28 and 4-1BB costimulatory signaling domains to a chimeric antigen receptor (CAR) specific for prostate-specific membrane antigen (PSMA). Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3 cytoplasmic domains in primary human CD8 T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice. Upon in vitro exposure to PSMA, the P28BBZ receptor-induced the strongest PI 3 Kinase/Akt activation and Bcl-X L expression, and the least apoptosis in transduced peripheral blood CD8 T cells. These findings further support the concept of integrating optimized costimulatory properties into recombinant antigen receptors to augment the survival and function of genetically targeted T cells within the tumor microenvironment.

AB - To enhance the strength of activation afforded by tumor antigen-specific receptors, we investigated the effect of adding combined CD28 and 4-1BB costimulatory signaling domains to a chimeric antigen receptor (CAR) specific for prostate-specific membrane antigen (PSMA). Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3 cytoplasmic domains in primary human CD8 T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice. Upon in vitro exposure to PSMA, the P28BBZ receptor-induced the strongest PI 3 Kinase/Akt activation and Bcl-X L expression, and the least apoptosis in transduced peripheral blood CD8 T cells. These findings further support the concept of integrating optimized costimulatory properties into recombinant antigen receptors to augment the survival and function of genetically targeted T cells within the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=76349087378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349087378&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.210

DO - 10.1038/mt.2009.210

M3 - Article

VL - 18

SP - 413

EP - 420

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -